Alex Zhavoronkov, PhD, a pioneer of generative artificial intelligence (AI) for biology and chemistry, and founder and CEO of Insilico Medicine (“Insilico”) will present at the Lab of the Future Congress at the Renaissance Boston Waterfront Hotel on March 9, 2pm ET.
In a talk titled “Novel Target Discovery and Molecular Design Using AI,” Dr. Zhavoronkov will share the breakthroughs and discoveries that have made Insilico Medicine a leader in generative AI drug discovery. This includes the development of Insilico’s end-to-end Pharma.AI platform for identifying novel targets (PandaOmics), designing new drugs (Chemistry42), and predicting the outcomes of clinical trials (InClinico). Also, how Insilico is partnering with top pharma companies like Fosun Pharma and Sanofi to advance their programs. Insilico is working with Fosun Pharma on IND-enabling studies to advance PCCs in the anti-cancer QPCTL program to clinical trials, and signed its largest partnership deal to date with Sanofi, a strategic research collaboration worth up to $1.2B, last year.
Dr. Zhavoronkov will also share progress on Insilico’s internal pharmaceutical pipeline. The Company’s lead drug for the devastating chronic lung disease idiopathic pulmonary fibrosis (IPF), the first AI-discovered and AI-designed drug to advance to clinical trials, will soon be entering Phase 2 trials with patients. And Insilico recently announced that its generative AI-designed drug for COVID-19 and related variants has been approved for clinical trials and offers a number of design advantages over existing COVID-19 drugs.
There are an additional 30 drugs in Insilico’s internal pipeline available for partnering and licensing for indications including cancer, fibrosis, and immunology.
Lab of the Future brings together hundreds of life science research leaders for the best attended congress on the future of biopharma R&D around the topics of innovation, collaboration and technology. The event is hosted by Open Pharma Research, which is dedicated to driving progress in the creation of a strategic and operational framework that allows scientists the freedom to innovate.
Founded in 2014, Insilico Medicine has raised over $400m in funding to date from notable biotech and tech investors and has won numerous awards, including, in 2022, the BioCentury-BayHelix Company of the Year award and Top 100 AI Companies by CB Insights.
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases. Headquartered in Hong Kong, Insilico Medicine has additional offices in New York, Montreal, Shanghai, Suzhou, Taipei, and Abu Dhabi. www.insilico.com
For media inquiries, please contact media@insilicomedicine.com
For business development, please contact bd@insilicomedicine.com
